Mancuso Roberta, Hernis Ambra, Agostini Simone, Rovaris Marco, Caputo Domenico, Clerici Mario
Don C. Gnocchi Foundation - ONLUS, P.zza Morandi, 3, 20100, Milano, Italy.
Department of Physiopathology and Transplantation, University of Milano, Milano, Italy.
J Transl Med. 2015 May 7;13:148. doi: 10.1186/s12967-015-0504-2.
Demyelination and failure of remyelination are core mechanisms in the pathogenesis of multiple sclerosis (MS); the factor(s) modulating these processes are still mostly unknown. MicroRNA 572 (miR-572) is deregulated in MS and is suggested to targets neural cell adhesion molecule (NCAM), a glycoprotein involved in CNS reparative mechanisms. The aim of this study is to analyze miR-572 in patients with different clinical phenotypes of MS.
qPCR quantification of miR-572 isolated from serum was performed in 16 primary progressive (PP), 15 secondary progressive (SP), 31 relapsing remitting (RR) MS patients and 15 sex-and age-matched healthy controls.
miR-572 expression was reduced overall in MS patients (p < 0.05) compared to HC; this miRNA was significantly upregulated in SPMS and in RRMS during disease relapse, whereas it was downregulated in PPMS and in quiescent phases of RRMS. miR-572 expression correlated with EDSS scores (RSp = 0.491; p < 0.05) independently of the clinical phenotype. The results suggest that this miRNA might be a tool that helps distinguishing between PPMS and SPMS and between relapsing and remitting phases in RRMS.
Evaluation of miR-572 may serve as a non-invasive biomarker for remyelination.
脱髓鞘和髓鞘再生失败是多发性硬化症（MS）发病机制的核心机制；调节这些过程的因素大多仍不清楚。微小RNA 572（miR-572）在MS中表达失调，并被认为靶向神经细胞黏附分子（NCAM），一种参与中枢神经系统修复机制的糖蛋白。本研究的目的是分析不同临床表型MS患者的miR-572。
对16例原发进展型（PP）、15例继发进展型（SP）、31例复发缓解型（RR）MS患者及15例年龄和性别匹配的健康对照者血清中分离的miR-572进行qPCR定量分析。
与健康对照相比，MS患者总体上miR-572表达降低（p<0.05）；在疾病复发期间，该微小RNA在继发进展型MS和复发缓解型MS中显著上调，而在原发进展型MS和复发缓解型MS的静止期则下调。miR-572表达与扩展残疾状态量表（EDSS）评分相关（RSp=0.491；p<0.05），且与临床表型无关。结果表明，这种微小RNA可能是一种有助于区分原发进展型MS和继发进展型MS以及复发缓解型MS复发和缓解期的工具。
miR-572的评估可作为髓鞘再生的一种非侵入性生物标志物。
